Key facts
- Solve Therapeutics’s last known valuation is $439.0M (Nov 2025).
- It has raised $384.5M across 3 recorded rounds; the latest was Early Stage VC ($48.2M) in Nov 2025.
- Notable investors include University of California, Alexandria Venture Investments, General Atlantic, Ally Bridge Group, Surveyor Capital — 16 tracked in total.
- Solve Therapeutics has filed 3 Form Ds with the SEC since 2022, most recently Nov 2025 ($48.2M sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Solve Therapeutics
Funding rounds
3 roundsAbout Solve Therapeutics
Operator of a drug development platform intended to develop novel antibody-drug conjugates. The company is developing bispecific therapeutics engineered for selectivity and optimized payload delivery, as well as novel patient-selection diagnostics, enabling medical professionals to help patients improve their lives and fulfill some unmet needs.
- Sector
- Healthcare
- HQ
- Belmont, CA, United States
- Founded
- 2021
- Employees
- 33
- Website
- solvetx.com/
- Ownership
- Privately Held (backing)
Solve Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Solve Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Solve Therapeutics in its N-PORT filings yet. We sweep new filings monthly.